Tryptamine Therapeutics

Kelowna, Canada

Tryp Identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.

$4.2M raised

May 2024

Post-IPO Equity

Biotechnology

Top Investors

Marc Lustig Jason Carroll

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Tryptamine Therapeutics

How much funding has Tryptamine Therapeutics raised?

Tryptamine Therapeutics has raised $4.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2024.

Who are Tryptamine Therapeutics's investors?

Tryptamine Therapeutics's investors include Marc Lustig, Jason Carroll.

Where is Tryptamine Therapeutics headquartered?

Tryptamine Therapeutics is headquartered in Kelowna, Canada.

What does Tryptamine Therapeutics do?

Tryp Identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.

What stage is Tryptamine Therapeutics at?

Tryptamine Therapeutics is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated May 1, 2024.

MLA

"Tryptamine Therapeutics — Funding & Investors." VCBacked, May 1, 2024, https://www.vcbacked.co/company/tryptamine-therapeutics. Accessed July 3, 2026.

APA

VCBacked. (2024). Tryptamine Therapeutics — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/tryptamine-therapeutics

Wikipedia (cite web)

{{cite web |title=Tryptamine Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tryptamine-therapeutics |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated May 1, 2024.